PCI Pharma Services

PCI is a large, global CDMO, providing integrated end-to-end drug development, manufacturing and packaging solutions throughout the product lifecycle, that increase product speed to market and opportunities for commercial success. The company’s proven experience includes more than 90 successful product launches each year, and more five decades in the delivery of supply-chain healthcare services.

PCI (which originally stood for Packaging Coordinators, Inc) has 30 GMP facilities in the US, Europe, Canada, Australia and Asia, and 5,500 employees. It is privately owned, a majority stake having been acquired by investment firm Partners Group on behalf of its clients in 2016, from investment firm Frazier Healthcare Partners , which purchased it as the US commercial pharma packaging operations of Catalent Pharma Solutions (itself originally a private equity acquisition (by Blackstone Group) from Cardinal Health Inc). Cardinal Health originally purchased Packaging Coordinators, Inc, in 1996. PCI acquired AndersonBrecon, the consumer packaging business of AmerisourceBergen Corp in 2017, and Penn Pharmaceutical Services, a UK provider of drug development and manufacturing services, in 2018.

Services offered include:

Drug Development & Manufacturing Solutions

PCI offerings full service formulation development including in-house analytical development services for both sterile and non-sterile dosage forms.  Its scalable development and manufacturing capabilities for tablets, capsules, gels, ointments, liquids, sterile dosage forms and lyophilized drug products are applied from early phase clinical trials through to commercialisation.

Advanced Drug Delivery

PCI’s design and development expertise combine with its sterile manufacturing, device assembly and advanced drug delivery packaging capabilities to offer flexible, innovative, patient centric solutions for a portfolio of conventional and specialty injectable drug-device combination products.  The company has the scalability to handle the dynamic volumes of biopharmaceutical therapies, whether large or small, from niche personalized medicines to large-volume treatments.

Commercial Packaging Technology

PCI has state-of-the-art packaging technologies, which allow it to provide advanced primary, secondary and tertiary packaging solutions for conventional dosage forms including oral solids, powders, liquids, creams and gels, as well as specialist injectable and parenteral delivery forms including vials, cartridges, prefilled syringes and autoinjectors.

Clinical Trial Services

Delivering over 200 protocols a year in over 100 countries, PCI supports the global supply of investigational medicines with pharmaceutical development, clinical drug product manufacturing, packaging, labeling, storage and distribution and full returns service.

What's this?